Trial ID or NCT#

NCT01778764

Status

RECRUITING

Purpose

The investigators will learn from this study if the CyberKnife radiosurgery (CK RS) treatment of patients with 1-3 versus 4 or more brain metastases results in the same overall survivals. The importance of this new knowledge will be to determine the treatment efficacy of CK RS with 1-3 versus 4 or more brain metastases. The outcome of this trial would give data to support either the continuation or modification of the CK RS treatment of patients with brain metastases.

Official Title

A Comparison of Overall Survival Post-CyberKnife Radiosurgery Treatment of Patients With 1-3 Versus 4 or More Brain Metastases

Eligibility Criteria

Ages Eligible for Study: 21 Years to 95 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Steven D. Chang, MD
Neurosurgeon, Aneurysm neurosurgeon, Cerebrovascular neurosurgeon, Pituitary tumors neurosurgeon, Stereotactic neurosurgeon, Neuro-oncologist
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology-Head and Neck Surgery
Judith Murovic
Iris C. Gibbs, MD, FACR
Radiation oncologist, Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Steven Chang
(650) 723-5573